Formulation, Characterization, and Stability of Protein Drugs

A Compendium and Hydropathy/Flexibility Analysis of Common Reactive Sites in Proteins: Reactivity at Asn, Asp, Gin and Met Motifs in Neutral pH Solution; M. Powell. Characterization, Stability, and Formulations of Basic Fibroblast Growth Factor; Y.J. Wang, et al. The Characterization, Stabilization, and Formulation of Acidic Fibroblast Growth Factor; D.B. Volkin, C.R. Middaugh. Stability, Characterization, Formulation, and Delivery System Development for Transforming Growth Factor-Beta1; W.R. Gombotz, et al. Stability and Characterization of Recombinant Human Relaxin; T.H. Nguyen, S.J. Shire. Interferon-£Ii£-1b (Betaserson): A Model for Hydrophobic Therapeutic Proteins; L.S. Lin, et al. Characterization, Formulation, and Stability of Neupogen (Filgrastim): A Recombinant Human Granulocyte Colony Stimulating Factor; A.C. Herman, et al. Development and Shelflife Determination of Recombinant Human Granulocytemacrophage Colonystimulating Factor (Leukin, GMCSF); J. Geigert, B.F.D. Ghrist. Formulation Development of an Antifibrin Monoclonal Antibody Radiopharmaceutical; M. Kamat, et al. Biophysical Characterization and Formulation of TP40: A Chimeric Protein which Requires a pHdependent Conformational Change for Its Biological Activity; G. Sanyal, et al. Stability Characterization and Formulation Development of Recombinant Human Deoxyribonuclease I [Pulmozyme, (Dornase Alpha)]; S.J. Shire. Index.